XML 20 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Megazyme Ltd And Subsidiary Megazyme Inc [Member]
Common Stock
Common Stock
Megazyme Ltd And Subsidiary Megazyme Inc [Member]
Additional Paid-in Capital
Additional Paid-in Capital
Megazyme Ltd And Subsidiary Megazyme Inc [Member]
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Non - Controlling Interest
Beginning Balance at May. 31, 2018 $ 560,175   $ 16,555   $ 194,295     $ 359,071 $ 0
Beginning Balance (in shares) at May. 31, 2018     103,471,464            
Exercise of options and share-based compensation expense 21,417   $ 164   21,253   $ (9,746)    
Exercise of options and share-based compensation expense (in shares)     1,025,054            
Issuance of shares under employee stock purchase plan $ 1,160   $ 6   1,154        
Issuance of shares under employee stock purchase plan (in shares) 36,660   36,660            
Shares repurchased $ (3,135)   $ (16)   (3,119)        
Shares repurchased (in shares)     (100,000)            
Net income 60,176             60,176 0
Other comprehensive gain (1,894)           (1,894)    
Ending Balance at May. 31, 2019 637,899   $ 16,709   213,583   (11,640) 419,247 $ 0
Ending Balance (in shares) at May. 31, 2019     104,433,178            
Exercise of options and share-based compensation expense 34,679   $ 227   34,452        
Exercise of options and share-based compensation expense (in shares)     1,415,348            
Issuance of shares under employee stock purchase plan $ 1,193   $ 7   1,186        
Issuance of shares under employee stock purchase plan (in shares) 43,156   43,156            
Net income $ 59,475             59,475  
Other comprehensive gain (8,069)           (8,069)    
Ending Balance at May. 31, 2020 $ 725,177   $ 16,943   249,221   (19,709) 478,722  
Ending Balance (in shares) at May. 31, 2020 105,891,682   105,891,682            
Exercise of options and share-based compensation expense $ 39,680   $ 226   39,454        
Exercise of options and share-based compensation expense (in shares)     1,410,948            
Issuance of shares under employee stock purchase plan $ 1,388   $ 6   1,382        
Issuance of shares under employee stock purchase plan (in shares) 38,406   38,406            
Issuance of shares for Megazyme acquisition   $ 4,916   $ 20   $ 4,896      
Issuance of shares for Megazyme acquisition (in shares)       127,268          
Net income $ 60,882           0 60,882  
Other comprehensive gain 8,334           8,334    
Ending Balance at May. 31, 2021 $ 840,377   $ 17,195   $ 294,953   $ (11,375) $ 539,604  
Ending Balance (in shares) at May. 31, 2021 107,468,304   107,468,304